- Home
- VTYX vs ACEL Comparison
VTYX vs ACEL Comparison
Compare VTYX & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTYX | ACEL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.9M | 942.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VTYX | ACEL |
|---|---|---|
| Price | $13.96 | $11.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $13.50 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 3.0M | 353.3K |
| Earning Date | 02-26-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $1,307,029,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $4.29 |
| P/E Ratio | ★ N/A | $22.53 |
| Revenue Growth | N/A | ★ 7.97 |
| 52 Week Low | $0.78 | $9.02 |
| 52 Week High | $25.00 | $13.28 |
Technical Indicators
Market Signals| Indicator | VTYX | ACEL |
|---|---|---|
| Relative Strength Index (RSI) | 73.84 | 49.09 |
| Support Level | $13.89 | $11.09 |
| Resistance Level | $13.98 | $11.46 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 43.72 | 44.12 |
Price Performance
Historical ComparisonAbout VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.